Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Topics
- Overview of mitochondrial disorders
- Electron transport chain
- Mitochondrial disorders
- Morbidity map
- Classic phenotypes in adults
- What genes cause OXPHOS disorders?
- Mitochondrial diagnosis
- Clinical features
- Clinical features in children
- My general approach
- My general approach (2)
- Biomarkers (blood, urine, CSF)
- My general approach (3)
- EM/LM changes
- Mitochondrial diagnosis – genetic
- Mitochondrial dysfunction
- Mitochondrial dysfunction (2)
- Treatment strategies – exercise
- Pathological disorders vs physiological adaptations
- Contractile activity determines phenotype (1)
- Gene shifting – satellite cell biology
- mtDNA gene shifting
- Resistance training in mitochondrial myopathy
- Muscle damage and regeneration in MM group
- Contractile activity determines phenotype (2)
- Endurance exercise in mitochondrial disease
- Endurance exercise training (1)
- Endurance exercise training (2)
- D257A knock-in – mutator mice
- Putting an END to aging
- Exercise attenuates many aging features.
- Endurance – brain atrophy & cardiac hypertrophy
- Endurance – skin histological alterations
- Encouraging exercise in children
- Treatment strategies – nutrition
- Nutritional inadequacy in patients with MD
- MD vs. mitochondrial disease
- Serum vitamin levels (1)
- Serum vitamin levels (2)
- Habitual diet (1)
- Habitual diet (2)
- What about a ketogenic diet for seizures?
- Habitual diet – high fat/ketogenic?
- What about other deficiencies?
- Clinical trials in mitochondrial disease
- Low muscle TCr/PCr stores
- Creatine in the body
- Potential benefit in mitochondrial disorders
- Benefit in mitochondrial disorders
- Mitochondrial disorders – CoQ10 treatment
- RCT of CoQ10 in mitochondrial disorders
- Idebenone and LHON
- Mito-cocktail approach (1)
- Mito-cocktail approach (2)
- Mito-cocktail approach (3)
- Mito-cocktail approach (4)
- Acknowledgements
Topics Covered
- Methods used in diagnosing mitochondrial cytopathies
- Common cellular metabolic pathways altered by mitochondrial dysfunction
- Evaluation of nutritional intake in patients with mitochondrial disease
- The use of exercise and nutrition for treatment of mitochondrial disorders
- Clinical evaluation of the role of exercise and nutrition
Talk Citation
Tarnopolsky, M. (2018, November 4). Exercise and nutrition in mitochondrial disorders [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 4, 2024, from https://doi.org/10.69645/EHMX2794.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Mark Tarnopolsky, Consulting Fees (e.g., advisory boards), Honoraria: 3 talks per year on approach to myopathy for Sanofi Genzyme; Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds): Exerkine Corporation - we have no commercial products yet and no plans for a mitochodnrial disease therapy in the next 3 vears at least.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
The title of the talk is "Exercise and Nutrition in Mitochondrial Disorders".
My name is Mark Tarnopolsky.
I'm a Professor of Pediatrics and Medicine at McMaster University in Hamilton, Canada.
0:13
What we'll be talking about today is an overview of mitochondrial cytopathies.
Then, we'll go into the diagnostic criteria for mitochondrial cytopathies.
We'll then talk about the consequences of mitochondrial dysfunction.
We'll move then into exercise therapy in mitochondrial disease and
finish with nutrition and nutraceutical therapies for mitochondrial disorders.
0:33
The mitochondria were thought to be
originally a purple photosynthetic bacteria which
invaded a protoeukaryotic cell about 1.5 billion years ago.
At the time, it was estimated that
approximately 1300 genes were used to encode for these bacteria.
Throughout the course of evolution,
there's been a sharing of the genetic material whereby
the original genetic material in the bacteria
is retained at something called the mitochondrial DNA.
This contains 37 genes.
Now, most of the proteins which encode for the bacteria,
now called the mitochondria,
are done so through the nuclear DNA.
In addition to the 22,000 genes that encode for other proteins,
1300 now encode for mitochondrial proteins.
The mitochondria are the main site for intermediary oxidative metabolism of fats,
proteins, and carbohydrates through the electron transport chain,
which we'll discuss in just a minute.
These are also important in apoptosis,
which is preprogrammed cell death,
the production of reactive oxygen species,
activation of the inflammasome,
and it's even been linked to aging through telomere length.
1:36
This slide shows the classic electron transport chain.
So, what we have here are essentially
the reducing equivalents from food used to provide substrates namely,
NADH plus H+
or succinate, or FADH2.
The potential energy is provided to Complex I and Complex II.
What happens is that this energy is used to move electrons along the respiratory chain,
which ultimately then reduces molecular oxygen to water at Complex IV.
But this energy is used to pump the protons,
which you can see at Complex I, III, and IV,
from the matrix of the mitochondria to the intermembrane space.
That potential energy is then used at Complex V to flow
back through the proton-motive force to rephosphorylate ADP back to ATP.
You can also see here, depicted in color,
those are the subunits of
the various respiratory chain complexes that are encoded for by mitochondrial DNA,
and the majority of them as you can see in gray are encoded for by the nuclear DNA.
This forms a series circuit essentially between Complex I,
III, IV, which is highly conserved throughout all of the vertebrate.
You can also see here coenzyme Q10,
which receives the electrons from both Complex I and Complex II.
And later on, we'll see that coenzyme Q10 is one of the therapeutic targets.